CVKD
Cadrenal Therapeutics, Inc. Common Stock NASDAQ Listed Jan 20, 2023$3.60
Mkt Cap $11.1M
52w Low $2.55
8.7% of range
52w High $14.64
50d MA $4.65
200d MA $8.00
P/E (TTM)
-0.6x
EV/EBITDA
—
P/B
2.6x
Debt/Equity
0.0x
ROE
-483.3%
P/FCF
-0.6x
RSI (14)
43.30
ATR (14)
$0.55
Beta
1.55
50d MA
$4.65
200d MA
$8.00
Avg Volume
85.9K
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
822 A1A North · Ponte Vedra, FL 32082 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -1.17 | -1.41 | -20.5% | 5.12 | +0.4% | -4.3% | -4.1% | -1.1% | -7.1% | +12.3% | — |
| Nov 10, 2025 | AMC | -1.55 | -1.31 | +15.5% | 11.76 | +0.9% | +5.0% | -0.9% | -4.8% | -0.3% | +0.8% | — |
| Aug 11, 2025 | AMC | -1.60 | -1.87 | -16.9% | 10.94 | +0.5% | -0.3% | +7.1% | +10.6% | -1.9% | +2.9% | — |
| May 8, 2025 | AMC | -1.64 | -2.09 | -27.4% | 15.50 | +3.0% | -6.8% | -7.4% | +10.5% | -4.4% | +7.1% | — |
| Mar 13, 2025 | AMC | -1.71 | -2.74 | -60.2% | 17.45 | +1.6% | +9.4% | +4.1% | -2.7% | +1.0% | -0.1% | — |
| Nov 7, 2024 | AMC | -1.83 | -2.18 | -19.1% | 16.29 | +1.2% | +8.9% | +0.8% | -0.9% | -6.6% | +0.1% | — |
| Aug 7, 2024 | AMC | -19.04 | -2.25 | +88.2% | 6.21 | -3.9% | +4.7% | -0.8% | +2.3% | +13.6% | +3.9% | — |
| May 9, 2024 | AMC | -1.05 | -1.50 | -42.9% | 7.28 | -1.1% | -5.2% | -4.3% | +0.2% | +0.6% | -3.0% | — |
| Mar 11, 2024 | AMC | -1.35 | -0.75 | +44.4% | 9.76 | -4.4% | -10.9% | +1.0% | +1.5% | -1.1% | -4.8% | — |
| Nov 9, 2023 | AMC | -1.05 | -1.05 | +0.0% | 6.60 | -3.8% | -4.1% | -2.8% | +2.3% | +16.9% | -7.9% | — |
| Aug 10, 2023 | AMC | — | -1.35 | — | 11.11 | +4.1% | +2.3% | +1.4% | -1.2% | -6.3% | +9.7% | — |
| May 10, 2023 | AMC | — | -0.41 | — | 22.05 | -4.8% | +4.1% | -8.5% | +0.7% | +3.5% | -2.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.65 | $4.50 | -3.2% | -7.1% | +12.3% | +2.5% | -4.2% | +4.8% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.14 | $15.16 | +0.1% | +2.4% | -1.0% | +2.1% | +0.1% | -4.3% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.74 | $18.00 | +1.5% | +0.8% | -0.9% | -6.6% | +0.1% | -5.5% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.65 | $7.79 | +1.8% | -2.0% | -5.9% | -6.2% | +6.3% | -0.6% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.36 | $7.20 | -2.2% | -1.1% | -5.2% | -4.3% | +0.2% | +0.6% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.79 | $8.79 | +0.0% | +1.5% | -1.1% | -4.8% | +1.8% | +5.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Pham Quang XDir/Off | Chairman and CEO | Sell | 7,400 | $3.03 | $22K | 98,589 | +13.56% | — |
| Jun 23, 2026 | Pham Quang XDir/Off | Chairman, CEO and Interim CFO | Sell | 2,277 | $3.20 | $7K | 117,145 | -4.03% | -5.09% |
| Jun 22, 2026 | Pham Quang XDir/Off | Chairman, CEO and Interim CFO | Sell | 9,167 | $3.55 | $33K | 119,422 | -4.03% | -5.09% |
| Jun 17, 2026 | Pham Quang XDir/Off | Chairman, CEO and Interim CFO | Sell | 513 | $3.16 | $2K | 128,589 | -9.14% | +6.64% |
| Jun 16, 2026 | Pham Quang XDir/Off | Chairman, CEO and Interim CFO | Sell | 3,613 | $3.18 | $11K | 129,102 | -9.14% | +6.64% |
| Jun 15, 2026 | Pham Quang XDir/Off | Chairman, CEO and Interim CFO | Sell | 3,666 | $3.58 | $13K | 132,715 | -8.71% | -3.77% |
| Jun 12, 2026 | Pham Quang XDir/Off | Chairman, CEO and Interim CFO | Sell | 12,996 | $3.94 | $51K | 136,381 | -8.71% | -3.77% |
| Jun 11, 2026 | Pham Quang XDir/Off | Chairman, CEO and Interim CFO | Sell | 1,462 | $4.12 | $6K | 149,377 | -8.71% | -3.77% |
| Jun 10, 2026 | Pham Quang XDir/Off | Chairman, CEO and Interim CFO | Sell | 3,500 | $4.21 | $15K | 150,839 | -2.66% | +1.97% |
| Jun 9, 2026 | Pham Quang XDir/Off | Chairman, CEO and Interim CFO | Sell | 12,992 | $4.06 | $53K | 154,339 | -2.66% | +1.97% |
| Jun 8, 2026 | Pham Quang XDir/Off | Chairman, CEO and Interim CFO | Sell | 5,893 | $4.38 | $26K | 167,331 | -2.66% | +1.97% |
| Jun 2, 2026 | Pham Quang XDir/Off | CEO and Chairman | Sell | 349 | $4.46 | $2K | 181,509 | -3.68% | -6.18% |
| May 29, 2026 | Pham Quang XDir/Off | CEO and Chairman | Sell | 303 | $5.01 | $2K | 181,858 | -3.68% | -6.18% |
| May 22, 2026 | Pham Quang XDir/Off | CEO and Chairman | Sell | 1,165 | $5.69 | $7K | 194,924 | -5.20% | -7.45% |
8-K · 1.01
! Medium
Cadrenal Therapeutics, Inc. -- 8-K 1.01: Equity Issuance
Jul 1
8-K · 5.02
!!! Very High
Cadrenal Therapeutics, Inc. -- 8-K 5.02: Executive Change
Jun 29
8-K · 8.01
!! High
Cadrenal Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 18
8-K · 5.02
!!! Very High
Cadrenal Therapeutics, Inc. -- 8-K 5.02: Executive Change
Jun 3
8-K · 2.02
!! High
Cadrenal Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Cadrenal Therapeutics reported Q1 2026 financial results on May 7, 2026, which investors can review in the accompanying press release for operational performance and cash position details.
May 7
8-K · 8.01
!! High
Cadrenal Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Cadrenal Therapeutics completed its FDA End-of-Phase 2 meeting for CAD-1005, receiving guidance on Phase 3 trial design for this heart inflammation treatment, potentially accelerating development timelines.
Apr 30
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
CVKD signed a $2.5 million material agreement, suggesting new revenue opportunities or strategic partnerships that could drive near-term growth and improve financial performance.
Apr 1
8-K
Unknown — 8-K Filing
Cadrenal Therapeutics filed an 8-K with a press release, signaling a material corporate announcement that could impact stock price; investors should review the full press release details to assess the announcement's significance.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Preclinical data supporting CAD-1005's potential efficacy in diabetes and obesity could validate Corvus's therapeutic approach and drive clinical trial advancement, offering significant upside if human trials show similar inflammatory and metabolic improvements.
Mar 12
8-K · 8.01
!! High
Cadrenal Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Cadrenal Therapeutics reports positive trial results for CAD-1005 in heparin-induced thrombocytopenia, potentially establishing a new surrogate endpoint through collaboration with previous sponsor Veralox Therapeutics.
Feb 24
Valuation
Market Cap
$11.1M
Enterprise Value
$3.2M
P/E (TTM)
-0.64x
Forward P/E
—
PEG Ratio
0.04x
P/B
2.62x
P/S
—
P/FCF
-0.57x
EV/EBITDA
—
Shares Out
2.0M
Financials (TTM)
Revenue
$0
Net Income
-$11.9M
EBITDA
-$11.9M
Free Cash Flow
-$12.6M
Op Cash Flow
-$12.6M
EPS Basic
$-6.64
EPS Diluted
$-5.63
EPS Forward
$-5.61
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$4.3M
Total Liab.
$1.6M
Total Equity
$2.7M
Cash
$4.0M
LT Debt
$0
Book Value/Sh
$1.37
Debt/Equity
0.00x
Current Ratio
2.72
Quick Ratio
2.72
Returns & Growth
ROE
-483.3%
ROA
-305.9%
ROIC
-491.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
+23.9%
Price Returns
2W
+16.1%
1M
-16.5%
3M
-22.6%
6M
-50.9%
12M
-72.2%
Technicals
52W High
$14.64
52W Low
$2.55
50d MA
$4.65
200d MA
$8.00
RSI (14)
43.30
ATR (14)
$0.55
Beta
1.55
Avg Volume
86K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$32.00
High
$32.00
Low
$32.00
Median
$32.00
Data updated apr 25, 2026 4:06am
· Source: financialmodelingprep.com